A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale

被引:316
作者
Eton, DT
Cella, D
Yost, KJ
Yount, SE
Peterman, AH
Neuberg, DS
Sledge, GW
Wood, WC
机构
[1] Evanston NW Healthcare, Evanston, IL 60201 USA
[2] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60201 USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Indiana Univ, Med Ctr, Indianapolis, IN USA
[5] Emory Univ, Atlanta, GA 30322 USA
关键词
breast cancer; minimal important difference; quality of life; health-related; Functional Assessment of Cancer Therapy-Breast questionnaire; clinical significance;
D O I
10.1016/j.jclinepi.2004.01.012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: To determine distribution- and anchor-based minimal important difference (MID) estimates for four scores from the Functional Assessment of Cancer Therapy-Breast (FACT-B): the breast cancer subscale (BCS), Trial Outcome Index (TOI), FACT-G (the general version), and FACT-B. Study Design and Setting: We used data from a Phase III clinical trial in metastatic breast cancer (ECOG study 1193; n = 739) and a prospective observational study of pain in metastatic breast cancer (n = 129). One third and one half of the standard deviation and I standard error of measurement were used as distribution-based criteria. Clinical indicators used to determine anchor-based differences included ECOG performance status, current pain, and response to treatment. Results: FACT-B scores were responsive to performance status and pain anchors, but not to treatment response. By combining the results of distribution- and anchor-based methods, MID estimates were obtained: BCS = 2-3 points, TOI = 5-6 points, FACT-G = 5-6 points, and FACT-B = 7-8 points. Conclusion: Distribution- and anchor-based estimates of the MID do show convergence. These estimates can be used in combination with other measures of efficacy to determine meaningful benefit and provide a basis for sample size estimation in clinical trials. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:898 / 910
页数:13
相关论文
共 46 条
  • [1] [Anonymous], 1996, J Clin Oncol, V14, P671
  • [2] [Anonymous], 2003, CANC FACTS FIG
  • [3] Ashing-Giwa K, 1999, CANCER, V85, P418, DOI 10.1002/(SICI)1097-0142(19990115)85:2<418::AID-CNCR20>3.0.CO
  • [4] 2-9
  • [5] ASHINGGIWA K, 1999, CANCER, V86, P732
  • [6] Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an eastern cooperative oncology group trial
    Bonomi, P
    Kim, KM
    Fairclough, D
    Cella, D
    Kugler, J
    Rowinsky, E
    Jiroutek, M
    Johnson, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) : 623 - 631
  • [7] Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument
    Brady, MJ
    Cella, DF
    Mo, F
    Bonomi, AE
    Tulsky, DS
    Lloyd, SR
    Deasy, S
    Cobleigh, M
    Shiomoto, G
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 974 - 986
  • [8] Primary care - Primary care for survivors of breast cancer
    Burstein, HJ
    Winer, EP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (15) : 1086 - 1094
  • [9] Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales
    Cella, D
    Eton, DT
    Lai, JS
    Peterman, AH
    Merkel, DE
    [J]. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 24 (06) : 547 - 561
  • [10] What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592
    Cella, D
    Eton, DT
    Fairclough, DL
    Bonomi, P
    Heyes, AE
    Silberman, C
    Wolf, MK
    Johnson, DH
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2002, 55 (03) : 285 - 295